严重急性呼吸综合征冠状病毒2：正在研发的疫苗
SARS-CoV-2 virus: Vaccines in development.
作者信息
Huang Qingrui, Yan Jinghua
机构信息
CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.
University of Chinese Academy of Sciences, Beijing 101408, China.
出版信息
Fundam Res. 2021 Mar;1(2):131-138. doi: 10.1016/j.fmre.2021.01.009. Epub 2021 Jan 22.
The ongoing COVID-19 pandemic, caused by SARS-CoV-2, is an unprecedented challenge to humanity. Global herd immunity may be necessary before resumption of normal economic and societal activities. Since the beginning of the outbreak, the development of COVID-19 vaccines has proceeded at record speed using nearly all available platforms or strategies to maximize vaccine success. A total of 42 vaccine candidates have now entered clinical trials and encouraging data from several vaccine candidates in phase 1 or 2 clinical trials have been reported. In this review, we examine current COVID-19 vaccine candidates, discuss their strengths and weaknesses, summarize published clinical data and analyze future challenges.
由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引发的新型冠状病毒肺炎（COVID-19）大流行，是人类面临的前所未有的挑战。在恢复正常经济和社会活动之前，全球群体免疫可能是必要的。自疫情爆发以来，COVID-19疫苗的研发以前所未有的速度推进，几乎采用了所有可用的平台或策略，以最大限度地提高疫苗研发的成功率。目前共有42种候选疫苗进入临床试验阶段，并且已有多项关于1期或2期临床试验中几种候选疫苗的令人鼓舞的数据报道。在这篇综述中，我们研究了当前的COVID-19候选疫苗，讨论了它们的优缺点，总结了已发表的临床数据，并分析了未来面临的挑战。
Zotero 插件